the aim of work In study the changes in plasma atrial natriuretic peptide (ANP) in
•. ukliv puln..marv di• '01'1)) :toil In correlate these changes with
the \ emit:miry and cardiac 'unctions. Sixt patients with MPH were selected Itom internal
medicine and clic'a dep.utinents at lienha I ;111VerSily Hospitals and were classilied into :t
pint's. gimp I Hu:Ruled 20 cases on ho•pilal admission ‘vith acute infective exacerbation
(group la) and [hest: cases were reinvestieated ô weeks alter medical treatment (Group lb).
poop II included taw:. with (019) col pulmonale and right sided hear t failure and
rroup III included 'II cases with COPD without cor-pulmonale Their ages ranged from 40 to
vcar. old I he•.c ;ilium,: of patient!, weir unmated with 10 healthy !intik-els matched wilh
the same age and sex. For all groups, plasma ANP, ventilatory functions and
echocardiography were done. The main results of the study, showed that plasma ANP was
significantly higher in group la in comparison to group lb . ANP was significantly elevated in
all groups, the highest level was in-group In while the lowest level was in-group III. ANP was
significantly elevated in group II in comparison to group lb and group III .Also, ANP was
correlated with mean pulmonary artery pressure (PAP), surface area of right atrium (SARA),
right atrial diameter (RAD), right ventricular diameter (RVD) and right ventricular anterior
wall diameter (RVAWD). The decrease of AN? in group lb was associated with improvement
in the ventilatory and cardiac functions. We could conclude that; ANP was elevated and
correlated with the severity of the disease in COPD cases. Also, it was correlated with the
degree of PAP, right atrial and ventricular dimensions. ANP may give a new meaning in the
future for the treatment of COPD cases . So, we recommend measurement of it's level in
patients with COPD to determine the severity of the disease and follow up it's level during the
course of the treatment because it is considered as a good indicator for the improvement of the
patient with COPD and the efficacy of the treatment. |
